PT-141

Most treatments for sexual dysfunction work below the neck — they affect blood flow or tissue sensitivity. Bremelanotide works differently: it targets receptors in the hypothalamus, a brain region involved in motivation and desire. By activating these receptors (primarily MC4R), it appears to increase sexual interest through neurochemical pathways involving dopamine. This central mechanism is why it is sometimes described as a "desire drug" rather than an "arousal drug." It was approved by the FDA in 2019 under the brand name Vyleesi as an as-needed injection for premenopausal women with hypoactive sexual desire disorder — low sexual desire that causes significant distress and is not explained by another condition, relationship problem, or medication. Off-label use, particularly in men with erectile dysfunction or low libido, is widespread but not backed by Phase III evidence. The approving Phase III trials showed modest (small-to-moderate) effect sizes, and an independent reanalysis has documented that most of the protocol-registered secondary outcomes were not reported in the primary publication — a transparency concern readers should weigh alongside the approval.

Bremelanotide is a cyclic heptapeptide lactam, an analog of the α-MSH fragment [Nle4,Asp5,D-Phe7,Lys10]α-MSH-(4-10), cyclized via an intramolecular lactam bond between the Asp5 β-carboxyl and Lys10 ε-amine. Cyclization confers proteolytic resistance and restricts conformational flexibility relative to the linear parent; the D-Phe7 substitution and N-terminal acetylation further increase metabolic stability and receptor binding affinity. Bremelanotide exhibits preferential agonist activity at melanocortin receptor subtypes MC3R and MC4R over MC1R and MC2R, with MC4R activation in hypothalamic circuits (particularly the paraventricular nucleus) considered the primary driver of central pro-sexual effects through downstream mesolimbic dopamine signaling. Pharmacokinetic profile following subcutaneous injection: near-complete bioavailability, Tmax ~1 hour, elimination half-life ~2.7 hours, clearance via peptide bond hydrolysis and renal excretion (~65%). The compound differs from Melanotan II by a single 1-Da C-terminal modification (-OH vs -NH2); unit-resolution mass spectrometry CANNOT reliably distinguish the two at m/z ~1025, which has direct QC implications for research-market supply. The approved dose is 1.75 mg SC as-needed ≥45 min before anticipated sexual activity, limited to ≤1 dose / 24 hours and ≤8 doses / month per label to limit hyperpigmentation risk.

• Nausea — 40.0% vs 1.3% placebo (RECONNECT). Most common reason for discontinuation; typically mild-to-moderate, onset within 1 hour, resolves in ~2 hours.
• Flushing — 20.3% vs 1.3% placebo. Mild-moderate; transient.
• Headache — 11.3% vs 1.9% placebo.
• Injection-site reactions — 5.4% vs 0.5% placebo (bruising, pain, erythema).
• Focal hyperpigmentation — <1% with label as-needed dosing; 38.2% with daily dosing for 8 days. Typical sites: face, gums, breasts. May not fully reverse after discontinuation per FDA label.
• Transient systolic BP increase +6 mmHg peak at 2–4 hours; resolves within 12 hours. Clinically relevant in patients with baseline hypertension.
• Transient diastolic BP increase +3 mmHg peak. Same time course.
• Transient heart-rate decrease −5 bpm, concurrent with BP changes.

• Uncontrolled hypertension (FDA label contraindication)
• Known cardiovascular disease (FDA label contraindication)
• Concurrent use with naltrexone (opioid receptor antagonist; listed precaution on FDA label)
• Pregnancy and lactation (no human safety data; FDA label warns against use)
• Postmenopausal women (FDA label explicitly excludes this population from the approved indication)
• Men (FDA label explicitly excludes; male use is off-label and outside Phase III evidence)
• Use for sexual performance enhancement in healthy individuals (not an approved use; no evidence base)

• Ethanol — one Phase I co-administration study; no clinically significant PK interaction. Still avoid heavy co-consumption due to overlapping vasodilatory and hypotension-vs-hypertension profiles.
• Naltrexone (oral or IV) — listed in the FDA label as potentially affecting response; avoid concurrent use.
• Antihypertensives — additive BP effect concern with the transient +6/+3 mmHg increase; clinically monitor.
• SSRIs / SNRIs — commonly co-prescribed in the HSDD population; formal PK/PD interaction data absent. Serotonergic agents interact with dopaminergic signaling downstream of MC4R, so an interaction at the pharmacodynamic level is biologically plausible but unstudied.
• PDE5 inhibitors (sildenafil, tadalafil) — one 19-man Phase II combination pilot with nasal bremelanotide + sildenafil; no interaction signal at those doses. Palatin Phase 2b SC combination trial ongoing. Risk-benefit of the combination in women has not been studied.
• Hormonal contraceptives — no formal interaction data despite overlap in the HSDD population.

No. They are related but distinct peptides. Both are synthetic α-MSH analogs, both act on MC4R for sexual effects, and both share the same cyclic heptapeptide lactam core sequence. The critical difference: bremelanotide has a free C-terminal hydroxyl (-OH) while Melanotan II has a C-terminal amide (-NH2) — a 1-Dalton difference in molecular weight (1025.18 vs 1024.20). Bremelanotide has substantially reduced MC1R activity compared to MT-II, meaning it causes less skin tanning. Bremelanotide (Vyleesi) is FDA-approved; MT-II has never been approved by any regulatory agency. Unit-resolution mass spectrometry CANNOT distinguish the two at m/z ~1025 — high-resolution MS is required. Research-market PT-141 supply shares infrastructure with MT-II, so substitution or cross-contamination is a plausible QC failure mode that standard COAs will not catch.

Possibly, but the evidence is insufficient to conclude yes at a clinical level. Phase II intranasal data (N=726) showed signal before development was halted in 2007 due to dose-dependent blood-pressure increases. A single-center observational report of 21 men (Goldstein & Goldstein 2024) reported improvement in 91% — but no control group, single site, and the conducting clinic prescribes bremelanotide commercially (significant COI). A Phase 2b combination trial (bremelanotide SC + PDE5i) is currently ongoing. Bremelanotide is NOT FDA-approved for any indication in men.

Peak plasma concentration is reached ~1 hour after subcutaneous injection. Elimination half-life is ~2.7 hours; most of the drug is cleared within 8–12 hours. Functional duration of effect (desire modulation) may extend somewhat beyond the plasma half-life because downstream neurochemical changes in dopaminergic circuits can outlast active receptor occupancy. RECONNECT trial protocols specified injection ≥45 minutes before anticipated sexual activity; the prescribing information does not quantify a duration-of-effect window. Clinicians commonly cite 4–8 hours of functional effect, but this figure is not derived from a published controlled duration study.

Nausea is the most common (40% vs 1.3% placebo in Phase III) and the leading cause of discontinuation; typically mild-to-moderate and resolves within 2 hours. Clinically most important: a transient blood-pressure increase of up to +6 mmHg systolic and +3 mmHg diastolic, peaking at 2–4 hours and resolving within 12 hours. In people with uncontrolled hypertension or cardiovascular disease, this is a contraindication (not just a caution) per the FDA label. Focal hyperpigmentation of the face, gums, and breasts is documented and may not fully reverse after discontinuation — risk is substantially higher with frequent dosing (38.2% with daily dosing for 8 days vs <1% with label as-needed dosing).

In the US, generally no for the approved indication. Bremelanotide is the active ingredient of FDA-approved Vyleesi, and under 21 U.S.C. § 503A(c) compounders generally may not compound a drug that is essentially a copy of an approved commercially available product. The FDA also previously classified bremelanotide as presenting significant safety concerns under its legacy bulk drug substance review framework ('Category 2'). Some compounding pharmacies prepare nasal sprays or sublingual troches (different routes from the approved SC product) and argue these are not 'essentially copies' — this is a legal grey area with variable FDA enforcement. Purchasing 'PT-141' from a research-peptide vendor or compounding pharmacy means you are not receiving an FDA-approved product; quality, potency, and identity (especially vs Melanotan II) are not independently verified.

Bremelanotide has LOWER MC1R activity than Melanotan II by design — it was specifically modified to reduce pigmentation effects. At the FDA-approved label dosing (as-needed, ≤8 doses/month), focal hyperpigmentation was rare (<1%) in RECONNECT. However, in a sub-study where healthy women received bremelanotide daily for 8 days, 38.2% developed focal hyperpigmentation of the face, gums, or breasts. People with darker skin tones may have higher susceptibility. These changes may not be fully reversible after discontinuation. Anyone using bremelanotide more frequently than the label recommends should be aware that tanning-like pigmentation changes are a real risk, particularly with chronic high-frequency use — but this is an ADVERSE effect, not a therapeutic tanning effect. Claims that PT-141 provides tanning conflate it with Melanotan II.

Both are FDA-approved for acquired, generalized HSDD in premenopausal women, but differ in almost every other respect. Flibanserin (Addyi) is NOT a peptide — it is a small-molecule triazolopyrimidine originally developed as an antidepressant and repurposed for HSDD. Flibanserin is daily oral; bremelanotide is as-needed SC injection. Flibanserin works via serotonin (5-HT1A agonist / 5-HT2A antagonist) and dopamine pathways; bremelanotide works via melanocortin receptors. Flibanserin has a black-box warning for CNS depression and hypotension with alcohol; bremelanotide has a cardiovascular warning (transient BP increase) and nausea. No published head-to-head comparison trial. Effect sizes for both are small-to-moderate in their respective trials; neither demonstrates transformative clinical effect.

I was unable to directly verify the 2026 WADA Prohibited List PDF during research (domain egress blocked). Melanocortin receptor agonists have been included on prior WADA Prohibited Lists under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to WADA testing should verify current status directly at wada-ama.org/en/prohibited-list before use. If prescribed for a documented medical condition (HSDD), a Therapeutic Use Exemption (TUE) may be available. Drug tests for bremelanotide are technically feasible via mass spectrometry and anti-doping labs have the capability to detect synthetic melanocortin peptides in urine and blood.

Five items, separately reported. (1) HIGH-RESOLUTION mass spectrometry confirmation of the expected [M+H]+ at m/z 1026.2 (free base) — unit-resolution MS CANNOT distinguish bremelanotide from Melanotan II (1 Da difference). HRMS >10,000 resolving power is required. (2) Explicit SALT-FORM declaration — free base vs acetate salt — and separate net peptide content (not just HPLC chromatographic purity). Acetate adds ~60 Da per molecule. (3) CHIRAL HPLC or circular dichroism confirming the D-Phe7 configuration — standard RP-HPLC and mass spec CANNOT detect L-Phe7 epimer contamination, which silently destroys MC4R affinity. (4) Explicit CYCLIC STRUCTURE confirmation — the uncyclized linear precursor has a +18 Da mass difference and correct HPLC retention but zero MC4R activity; high-resolution MS separates them. (5) Endotoxin (LAL) per USP <85> and sterility testing for an injectable product. A COA showing only '≥98% HPLC purity' without these five items has not meaningfully characterized what is in the vial — and cannot rule out MT-II substitution, D-Phe7 epimer contamination, or uncyclized-precursor mislabeling.